Sera Prognostics (SERA) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was $29,000, down from $42,000 in Q3 2023, with a net loss of $7.9 million compared to $7.2 million year-over-year, reflecting continued investment in commercialization, R&D, and foundational growth initiatives.

• Operating expenses increased 8% to $8.9 million, mainly due to non-cash stock compensation and growth investments.

• Commercial initiatives included national awareness campaigns, direct-to-consumer and home collection kit launches, and key hires in sales and marketing.

• PRIME study data analysis completed, with publication and conference presentations planned for early 2025, expected to be pivotal for commercial and clinical progress.

• Transition to ambient whole blood collection improved access, reduced costs, and increased lab capacity.

Financial highlights

• Q3 2024 net revenue was $29,000, down from $42,000 in Q3 2023; nine-month revenue was $53,000, down from $265,000 year-over-year.

• Net loss for Q3 2024 was $7.9 million, compared to $7.2 million in Q3 2023; nine-month net loss was $24.3 million, an improvement from $28.3 million year-over-year.

• Operating expenses for Q3 2024 totaled $8.9 million, up from $8.2 million in Q3 2023; nine-month operating expenses were $27.3 million, down from $31.2 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $74.3 million as of September 30, 2024, with a projected year-end cash balance of $68 million and runway into 2027.

• Weighted-average shares outstanding for Q3 2024 were 33.5 million.

Outlook and guidance

• PRIME study results expected to be published and presented at key conferences in early 2025, anticipated to drive payer and guideline adoption.

• Gross cash expenses for 2024 expected to be under $30 million, with a similar target for 2025 as commercial investments increase.

• Management expects continued operating losses and negative cash flows as commercialization and R&D activities persist.

• Future revenue growth depends on broader market adoption, successful payer contracts, and commercialization of pipeline products.